NASDAQ$NKTX
Nkarta Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the third quarter ended September 30, 2024.
Nkarta reported a cash balance of $405.3 million as of September 30, 2024, which is expected to fund operations into late 2027. The company is prioritizing the advancement of NKX019 for multiple autoimmune diseases and forgoing further development of NKX019 in lymphoma.
- First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studies
- Enrollment in Ntrust-2 expected to initiate by year-end 2024
- Preliminary clinical data from Ntrust-1 and Ntrust-2 clinical trials planned for 2025
- Platform prioritized to focus on advancement of NKX019 for multiple autoimmune diseases
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$0
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into late 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
+0.4%
Avg return
Earnings day
-2.5%
Avg return
5 days after
+1.4%
Avg return
30 days after
61%
14 / 23 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.5% | -16.1% | — | |
| Q4 2025 | +0.9% | -0.9% | +37.1% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro